Eli Lilly and - LLY Stock Forecast, Price & News

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Analysts Set New Price Targets

LLY has been the topic of a number of recent research reports. Mizuho increased their target price on Eli Lilly and from $315.00 to $356.00 in a research note on Monday, May 2nd. JPMorgan Chase & Co. raised their target price on Eli Lilly and from $340.00 to $355.00 in a research report on Wednesday, June 1st. StockNews.com lowered Eli Lilly and from a "strong-buy" rating to a "buy" rating in a research report on Friday, August 5th. Morgan Stanley boosted their target price on Eli Lilly and from $369.00 to $395.00 and gave the company an "overweight" rating in a research report on Friday, July 8th. Finally, SVB Leerink assumed coverage on Eli Lilly and in a research note on Monday, May 23rd. They set an "outperform" rating and a $341.00 price target for the company. Three analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $317.00.

Eli Lilly and Stock Performance

NYSE:LLY opened at $304.61 on Thursday. Eli Lilly and has a twelve month low of $220.20 and a twelve month high of $335.33. The company has a current ratio of 1.10, a quick ratio of 0.85 and a debt-to-equity ratio of 1.70. The firm has a market capitalization of $289.43 billion, a price-to-earnings ratio of 48.58, a PEG ratio of 2.25 and a beta of 0.35. The firm's fifty day simple moving average is $315.47 and its 200 day simple moving average is $290.16.

Eli Lilly and (NYSE:LLY - Get Rating) last issued its quarterly earnings results on Thursday, August 4th. The company reported $1.25 earnings per share for the quarter, missing analysts' consensus estimates of $1.86 by ($0.61). Eli Lilly and had a return on equity of 85.58% and a net margin of 19.58%. The company had revenue of $6.49 billion during the quarter, compared to analyst estimates of $6.85 billion. During the same period in the prior year, the company posted $1.87 earnings per share. The company's revenue was down 3.7% on a year-over-year basis. As a group, equities research analysts expect that Eli Lilly and will post 7.98 earnings per share for the current fiscal year.

Eli Lilly and Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, September 9th. Investors of record on Monday, August 15th will be given a dividend of $0.98 per share. This represents a $3.92 dividend on an annualized basis and a dividend yield of 1.29%. The ex-dividend date of this dividend is Friday, August 12th. Eli Lilly and's dividend payout ratio (DPR) is currently 62.52%.

Insider Buying and Selling at Eli Lilly and

In other news, major shareholder Lilly Endowment Inc sold 215,000 shares of the firm's stock in a transaction dated Friday, June 24th. The shares were sold at an average price of $324.31, for a total value of $69,726,650.00. Following the transaction, the insider now owns 104,203,810 shares of the company's stock, valued at approximately $33,794,337,621.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and stock in a transaction that occurred on Wednesday, June 1st. The shares were sold at an average price of $313.44, for a total value of $313,440.00. Following the sale, the chief accounting officer now directly owns 6,274 shares in the company, valued at $1,966,522.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 215,000 shares of the business's stock in a transaction dated Friday, June 24th. The shares were sold at an average price of $324.31, for a total transaction of $69,726,650.00. Following the completion of the sale, the insider now directly owns 104,203,810 shares of the company's stock, valued at approximately $33,794,337,621.10. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,195,396 shares of company stock worth $380,134,601. 0.12% of the stock is currently owned by corporate insiders.